Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study
JCO Clinical Cancer Informatics · 2026-01 · 10 (1)
DOI: 10.1200/cci-25-00159 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Clinical Cancer Informatics, 2026-01. Verfasst von Matthias Vanderkerken und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium. Hauptthemen laut MEDLINE: Artificial Intelligence, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Chronic lymphocytic leukemia (CLL) treatment paradigms have evolved significantly, yet real-world evidence (RWE) on guideline implementation and patient characteristics remains limited. MATERIALS AND METHODS This multicenter retrospective study leveraged artificial intelligence (AI) to analyze structured and unstructured data from four Belgian hospitals (January 1, 2018-October 31, 2021). Structured data including diagnosis codes, laboratory results, treatment records, and national registries were standardized using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Unstructured clinical notes and reports were processed using a transformer-based natural language processing (NLP) pipeline. We examined clinical characteristics, diagnostic testing, and treatment patterns among patients with newly diagnosed CLL. RESULTS Of 22 variable groups analyzed, 50.0% was derived from structured data only, 36.4% from unstructured data only (NLP-extracted), and 13.6% from mixed sources. Five hundred eighty-six patients with CLL were identified, with a median age of 74 years. One hundred seventy-four patients (29.7%) initiated first-line (1L) treatment, and 41 progressed to second-line treatment. Of 1L treated patients, 68.4% had at least one prespecified comorbidity, including 12.1% with significant cardiovascular disease. TP53 /del17p testing was documented in 34.3% of patients before 1L treatment, with aberrations detected in 42.8%. Bruton's tyrosine kinase inhibitors (BTKi; 35.6%) were the most common 1L treatment, followed by chemoimmunotherapy (CIT; 25.9%). CIT use declined (30.6% to 17.5%), whereas BTKi use remained stable (34.2% to 38.1%) between 2018 and 2021. CONCLUSION This AI-augmented study demonstrates the feasibility and scalability of combining NLP-derived insights with OMOP-standardized structured data to generate reproducible RWE in hematology. Our results highlight an elderly CLL population with significant comorbidities and a shift toward targeted therapies. While treatment patterns aligned with guidelines, data quality depended on source documentation accessibility. Improved integration of molecular testing into electronic health records is essential for enhancing clinical decision making, patient outcomes, and future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.
- Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Edegem, Belgium.
- Department of Hematology, AZ Groeninge, Kortrijk, Belgium.
- Department of Hematology, AZ Maria Middelares, Ghent, Belgium.
- Department of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Edegem, Belgium.
- Department of Hematology, UZ Leuven Gasthuisberg, Leuven, Belgium.
ORCID-Profile: Matthias Vanderkerken, Koen Van Eygen, Annelies Verbiest, Kristof Theys, Katoo Muylle, Ann De Becker
Zitieren
APA
Vanderkerken, M., Van Eygen, K., Galle, V., Verbiest, A., Janssens, A., Masuy, I., Theys, K., Cuppens, T., Muylle, K., & De Becker, A. (2026). Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study. JCO Clinical Cancer Informatics, 10(1). https://doi.org/10.1200/cci-25-00159
Vancouver
Vanderkerken M, Van Eygen K, Galle V, Verbiest A, Janssens A, Masuy I, et al. Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study. JCO Clinical Cancer Informatics. 2026;10(1). doi:10.1200/cci-25-00159
BibTeX
@article{Vanderkerken2026,
author = {Vanderkerken, Matthias and Van Eygen, Koen and Galle, Veerle and Verbiest, Annelies and Janssens, Ann and Masuy, Imke and Theys, Kristof and Cuppens, Tine and Muylle, Katoo and De Becker, Ann},
title = {Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study},
journal = {JCO Clinical Cancer Informatics},
year = {2026},
volume = {10},
number = {1},
doi = {10.1200/cci-25-00159}
}
EUVIMED